How Much Does Medical Device Software Development Cost? (2026 Guide)

Medical device software development cost is driven primarily by the device’s risk classification, not by how many features it has. A low-risk wellness companion app and a Class C diagnostic tool can carry an almost identical feature list and still differ several times over in total cost, because the higher-risk build must produce far more verification, validation, and regulatory documentation before it can safely reach a patient. Put plainly, you are budgeting for documented evidence of safety, not just for working software.

This guide covers medical device software development cost end to end: the drivers regulated teams routinely underestimate, how cost scales with IEC 62304 safety class and project stage, the models you can use to engage a partner, and how to arrive at a defensible number for your own program. It is written for MedTech manufacturers, SaMD and digital health founders, and in-house engineering leads scoping a first regulated build.

Why does medical device software cost more than a standard app?

Because you are not paying for features, you are paying for evidence. A consumer app can ship, break, and be patched next sprint. A regulated device cannot. Every requirement must trace to a test, every risk to a control, and every release to an auditable record before it reaches a patient. For higher-risk devices, that verification, validation, and regulatory documentation work often rivals or exceeds the effort of writing the software itself.

This is the difference that reshapes a budget. Ailoitte’s medical device software development services put the IEC 62304 software lifecycle and ISO 14971 risk management at the center of engineering rather than bolting them on before a submission. The risk management file and the design and development file, the record the FDA’s Quality Management System Regulation now recognizes in place of the legacy Design History File, are engineering deliverables produced alongside the code, not paperwork assembled at the end. That discipline is also what keeps the total cost predictable, which is the theme running through the rest of this guide.

What determines the cost of medical device software development?

Seven drivers determine the cost of medical device software development, and device risk class is the largest of them. Feature count matters far less than most teams expect. The drivers below, in rough order of impact, are what actually move a scoped estimate up or down.

• Device safety class (IEC 62304 A, B, C). The single biggest multiplier. A higher class means deeper verification and validation and heavier documentation.
• SaMD vs SiMD vs software accessory. Software in a device (embedded firmware, hardware constraints) carries different effort than standalone Software as a Medical Device or a companion app.
• Number and complexity of device integrations. Each connected device, sensor, and protocol such as Bluetooth LE or cellular IoT adds surface area to verify and validate.
• Interoperability requirements. FHIR R4, HL7, and DICOM integrations each carry engineering and testing cost so the software exchanges data cleanly across the clinical ecosystem.
• Regulatory pathway and target markets. An FDA 510(k), De Novo, or PMA submission, or an EU MDR or IVDR route, each changes how much documentation your team must produce.
• Cybersecurity requirements. Since March 2023, Section 524B of the US FD&C Act requires manufacturers of “cyber devices” to include cybersecurity information in premarket submissions, including a software bill of materials and a plan to monitor and patch postmarket vulnerabilities. Per the US FDA, submissions that lack it can be refused, and as of February 2026 these expectations are integrated with the Quality Management System Regulation and ISO 13485. This adds design, testing, and documentation cost.
• Delivery scope. A proof of concept, an MVP, and a full production product are three very different budgets, covered in detail below.

These drivers compound rather than simply add up. A remote patient monitoring platform that streams vitals from two connected devices over Bluetooth LE, integrates with an EHR through FHIR R4, and falls into Class B carries the weight of the class, the integrations, and the interoperability at the same time, and each one enlarges the verification surface the others sit on. This is why two products that look almost identical in a demo can be scoped very differently. The estimate follows the risk and the connections, not the number of screens.

Which costs get underestimated in medical device software budgets?

The most underestimated costs are verification and validation, regulatory documentation, continuous risk management, and post-market support. These are not optional extras. They are the difference between software that runs and software that can be cleared and marketed.

• Verification and validation. Multi-level testing from unit to system to validation, with full requirement-to-test traceability, is a significant line item in its own right for higher-class devices.
• Regulatory documentation and the design and development file. The software development plan, design specifications, and the design record itself are engineering deliverables that take real time to produce.
• A continuously maintained risk file. An ISO 14971 risk management file that is kept current, not reconstructed before submission, costs less overall precisely because it avoids late rework.
• Post-market support. Security patching, performance monitoring, change control, and the postmarket vulnerability management now expected under FDA cybersecurity rules all continue after launch and preserve your compliance posture.
• Rework from late compliance. The most avoidable cost of all, and the subject of the insight above.

How much does regulatory documentation actually add to the cost?

For higher-risk devices, regulatory documentation is one of the largest single cost centers, and for a Class C program it can rival the engineering effort itself. It is not one document but a connected evidence trail that has to be produced and kept current across the whole lifecycle. The main components are consistent across most programs.

• The software development plan and design specifications that define what is being built and how.
• The ISO 14971 risk management file, linking each identified hazard to a control and to the verification evidence that shows the control works.
• Verification and validation records, including the requirement-to-test matrix that proves every requirement was tested.
• The design and development file (formerly the Design History File, or DHF) that assembles the evidence for an FDA 510(k), De Novo, or PMA submission, or for EU MDR and IVDR review.

The cost lever here is timing, not volume. Documentation produced alongside the code is an ordinary part of engineering. Documentation reconstructed before a submission is a scramble that forces re-testing and re-work, which is exactly why Ailoitte’s medical device software development services generate this evidence continuously instead of at the end.

How do engagement models change what you pay?

The engagement model changes not just the sticker price but the total cost of ownership and how predictable it is. Ailoitte’s medical device software development services run under four models, each suited to a different level of scope certainty.

• Fixed price. Best when scope is stable. A pre-agreed quote with payments tied to milestones, so the budget is known up front.
• Time and materials. Best when scope will evolve, with monthly reporting and billing against real progress.
• AI Velocity Pods. Fixed-price, outcome-based delivery from a dedicated pod, accelerated by AI-native engineering without loosening the controls a regulated device requires.
• Dedicated team or augmentation. Extend your own engineering with regulated-healthcare specialists who work inside your process and quality system.

What should a medical device software development quote include?

A credible quote prices the safety work explicitly, not just the build. If verification, the risk file, and documentation are missing from the line items, the number is not lower, it is incomplete. Use the checklist below to compare vendors on the same basis.

• The software safety class assumed, and what changes to the estimate if the classification moves.
• Verification and validation scope, with requirement-to-test traceability stated as part of the work.
• Regulatory documentation and the design and development file listed as named deliverables, not assumptions.
• The risk management file, maintained across the lifecycle rather than assembled just before submission.
• Post-market support: security patching, monitoring, change control, and postmarket vulnerability management.
• The engagement model and how scope changes are priced and approved.

How can you reduce medical device software cost without compromising compliance?

You reduce medical device software development cost by removing rework, not by cutting safety work. The levers below lower total spend while keeping the submission on track.

• Nail intended use and classification early so scope does not thrash after development starts.
• Produce documentation alongside the code rather than in a submission-time scramble.
• Design a configurable architecture so adding a new device type does not mean a rebuild.
• Choose a partner with an existing IEC 62304 lifecycle instead of paying one to build that lifecycle on your program.

Is it cheaper to build medical device software in-house or outsource?

It depends on whether you already have a regulated software lifecycle and the people to run it. Building in-house can make sense when device software is your long-term core capability and you can carry the fixed cost of a quality system, a regulatory function, and specialist engineers between programs. Outsourcing to a partner that already operates an IEC 62304 lifecycle is usually faster and lower-risk for a first regulated product, because you are not funding the setup of that lifecycle from scratch. Many teams blend the two, extending an in-house group with medical device software development specialists for the regulated and interoperability-heavy work. Ailoitte delivers this as part of its broader healthcare software development practice.

What does this look like in delivered work?

The same engineering foundations behind these healthcare builds underpin Ailoitte’s medical device software development services: connected care at scale, HIPAA-compliant telehealth, and companion apps for connected health devices.

• AssureCare — a connected, patient-centered care platform with EHR and care-management modules serving millions of members.
• Mindfully — a HIPAA-compliant telehealth platform with encrypted video therapy and provider dashboards.
• Dr. Morepen — a companion app for a maker of connected home-health devices, integrating device tracking and education.

You can browse the full healthcare portfolio, or see how AI is applied to clinical workflows in healthcare EMR automation. More on the regulatory side is on the Ailoitte blog.

Discover how Ailoitte AI keeps you ahead of risk

Let's Talk

Sunil Kumar

Sunil Kumar is CEO of Ailoitte, an AI-native engineering company building intelligent applications for startups and enterprises. He created the AI Velocity Pods model, delivering production-ready AI products 5× faster than traditional teams. Sunil writes about agentic AI, GenAI strategy, and outcome-based engineering. Connect on LinkedIn